Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery

Published: March 28, 2016

Author: Peng-Yu Yang, Huafei Zou, Elizabeth Chao, Lance Sherwood, Vanessa Nunez, Michael Keeney, Esi Ghartey-Tagoe, Zhongli Ding, Herlinda Quirino, Xiaozhou Luo, Gus Welzel, Guohua Chen, Parminder Singh, Ashley K. Woods, Peter G. Schultz, and Weijun Shen

Journal: PNAS

Abstract

Antidiabetic treatments aiming to reduce body weight are currently gaining increased interest. Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist administered twice daily via s.c. injection, improves glycemic control, often with associated weight reduction. To further improve the therapeutic efficacy of exendin-4, we have developed a novel peptide engineering strategy that incorporates a serum protein binding motif onto a covalent side-chain staple and applied to the peptide to enhance its helicity and, as a consequence, its potency and serum half-life. We demonstrated that one of the resulting peptides, E6, has significantly improved half-life and glucose tolerance in an oral glucose tolerance test in rodents. Chronic treatment of E6 significantly decreased body weight and fasting blood glucose, improved lipid metabolism, and also reduced hepatic steatosis in diet-induced obese mice. Moreover, the high potency of E6 allowed us to administer this peptide using a dissolvable microstructure-based transdermal delivery system. Pharmacokinetic and pharmacodynamic studies in guinea pigs showed that a single 5-min application of a microstructure system containing E6 significantly improved glucose tolerance for 96 h. This delivery strategy may offer an effective and patient-friendly alternative to currently marketed GLP-1 injectables and can likely be extended to other peptide hormones.  Go to Article Link